Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications

NEXT STORY
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
PREV STORY
Biopharma Leaders Unite to Stand with Science
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aphios Is Developing Pathogen Inactivation Technology For Human Plasma Units

WOBURN, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Aphios Corporation today announced that it ...

author_avatar
NASDAQ Market News

OV’s method can predict if neoadjuvant treatment with doxorubicin in breast cancer will be successful, data published in ASCO journal

author_avatar
NASDAQ Market News

Oligonucleotide Synthesis Market Worth $3.9 Billion by 2025, Growing at a CAGR of 10.4% from 2019- Global Opportunity Analysis and Industry Forecasts by Meticulous Research®

author_avatar
NASDAQ Market News